Home / Community / News / News


10/03/2015 - 5:53pm

Many of you know that the Phase I/II clinical trial for a potential therapy, ISIS-DMPKRx, for people with myotonic dystrophy type 1 (DM1) has been underway since last December. The trial is still actively recruiting participants.

10/03/2015 - 6:13pm

On September 18th, DM community leaders and their families from across the country visited with their Senators and Representatives urging action on the 21st Century Cures Act.  MDF is following up on this successful advocacy campaign with our first ever DM Congressional Call-In on October 13th.

09/23/2015 - 3:14pm

Every year, the MDF Conference provides a friendly, welcoming place for people with DM to learn from one another and hear from an incredibly diverse array of scientists, researchers, advocates and community members with one thing in common: a belief that every person with DM deserves a high quality of life, and that learning from each other strengthens us all.

Dr. Hinman with Dr. Andy Berglund
09/10/2015 - 2:07pm

Although up to 25% of people with myotonic dystrophy report that gastrointestinal symptoms are their most troubling issue, we still understand little about their cause. MDF Fellow Dr. Melissa Hinman at the University of Oregon is tackling this issue with Dr. Andy Berglund of the University of Florida using zebrafish models.

09/10/2015 - 11:31am

MDF Chief Science Officer Sharon Hesterlee shares her initial thoughts on the newly-released FDA draft guidance for industry on drug development for rare diseases.


© Myotonic Dystrophy Foundation. All rights reserved.